10.48047/jocaaa.2025.34.07.10

EGFR-targeted gelatin nanoparticles observation method and process

Dr. Huda Begam
Department of Chemistry
RKDF University, Gandhi Nagar, Bhopal (M.P.) 462033
E-Mail:ziahudakhan.khan@gmail.com

Abstract

Epidermal growth factor receptor (EGFR)-targeted gelatin nanoparticles represent a promising approach for cancer therapy through selective drug delivery to EGFR-overexpressing tumor cells. This research paper comprehensively examines the observation methods and analytical processes for characterizing EGFR-targeted gelatin nanoparticles, focusing on their synthesis, modification, and therapeutic applications. The study evaluates various characterization techniques including transmission electron microscopy (TEM), scanning electron microscopy (SEM), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), and in vitro cellular assays. Primary data analysis reveals that GE11 peptide-modified gelatin nanoparticles demonstrate enhanced cellular uptake in EGFR-positive cancer cell lines, with particle sizes ranging from 150-300 nm and encapsulation efficiencies exceeding 85%. Secondary data analysis from recent studies indicates significant therapeutic improvements, with targeted formulations showing 60-75% greater efficacy compared to non-targeted controls in various cancer models. The findings demonstrate that multi-modal characterization approaches are essential for optimizing EGFR-targeted gelatin nanoparticle systems, providing critical insights for translating these therapeutic platforms from laboratory research to clinical applications.

Keywords

EGFR targeting, gelatin nanoparticles, GE11 peptide, cancer therapy, nanoparticle characterization, drug delivery, analytical methods, TEM analysis, cellular uptake

Introduction

Cancer remains one of the leading causes of mortality worldwide, with traditional chemotherapy often limited by poor selectivity and severe systemic toxicity (1). The emergence of nanotechnology-based drug delivery systems has revolutionized cancer treatment by enabling targeted therapeutic approaches that can specifically accumulate within tumor tissues while minimizing off-target effects (2). Among various nanocarrier platforms, gelatin nanoparticles have garnered significant attention due to their excellent biocompatibility, biodegradability, and versatile surface modification capabilities (3).

Epidermal growth factor receptor (EGFR) represents one of the most extensively studied molecular targets in cancer therapy, being overexpressed in numerous solid tumors including

10.48047/jocaaa.2025.34.07.10

pancreatic, lung, colorectal, and breast cancers (4). The receptor's overexpression correlates with poor prognosis, increased metastatic potential, and resistance to conventional therapies, making it an attractive target for precision medicine approaches (5). EGFR-targeted therapy has evolved from monoclonal antibodies like cetuximab and panitumumab to more sophisticated nanoparticle-based delivery systems that can simultaneously target cancer cells and deliver therapeutic payloads (6).

The development of EGFR-targeted gelatin nanoparticles involves complex physicochemical processes that require comprehensive characterization to ensure optimal therapeutic performance. Current research has focused on various targeting ligands, including full-length antibodies, antibody fragments, natural ligands like epidermal growth factor (EGF), and synthetic peptides such as GE11 (7). Among these options, the GE11 peptide (YHWYGYTPQNVI) has emerged as a particularly promising targeting moiety due to its small size, low immunogenicity, and specific binding affinity to EGFR without activating downstream signaling pathways (8).

The observation and characterization of EGFR-targeted gelatin nanoparticles present unique analytical challenges due to their complex structure, dynamic behavior in biological environments, and need for multi-parameter assessment. Traditional characterization methods must be adapted and optimized to provide accurate information about particle size distribution, surface morphology, targeting ligand density, drug loading efficiency, and biological performance (9). Furthermore, the development of standardized analytical protocols is crucial for ensuring reproducibility and facilitating regulatory approval of these therapeutic systems.

Recent advances in analytical instrumentation and imaging techniques have significantly enhanced our ability to characterize nanoparticle systems at the molecular level. High-resolution transmission electron microscopy, advanced light scattering techniques, and sophisticated cell-based assays now provide unprecedented insights into nanoparticle structure-function relationships (10). However, the integration of these various analytical approaches into comprehensive characterization workflows remains a significant challenge in the field.

Objectives

• To evaluate and optimize analytical methods for comprehensive characterization of EGFR-targeted gelatin nanoparticles including morphological, physicochemical, and biological properties

• To investigate the synthesis and surface modification processes for incorporating GE11 peptide targeting ligands onto gelatin nanoparticle surfaces with high efficiency and stability

• To assess the performance of various imaging techniques including TEM, SEM, and confocal microscopy for visualizing nanoparticle structure and cellular interactions

• To develop standardized protocols for measuring drug encapsulation efficiency, release

10.48047/jocaaa.2025.34.07.10

kinetics, and targeting specificity of EGFR-directed gelatin formulations

10.48047/jocaaa.2025.34.07.10

• To analyze cellular uptake mechanisms and therapeutic efficacy of targeted nanoparticles in EGFR-positive cancer cell models using quantitative analytical approaches

• To establish correlations between nanoparticle physicochemical properties and biological performance through systematic data analysis and statistical modeling

Scope of Study

• Comprehensive review and analysis of current literature on EGFR-targeted gelatin nanoparticle systems, focusing on publications from 2020-2024 to capture recent technological advances

• Evaluation of multiple characterization techniques including electron microscopy (TEM/SEM), dynamic light scattering (DLS), zeta potential analysis, and spectroscopic methods (FTIR, UV-Vis)

• Assessment of various EGFR targeting strategies with emphasis on GE11 peptide modification and alternative targeting ligands for comparison

• Analysis of in vitro cellular studies using EGFR-positive cancer cell lines including A549, Panc-1, SW480, and HeLa cells to evaluate targeting specificity and therapeutic efficacy

• Investigation of nanoparticle synthesis methods including desolvation, nanoprecipitation, and emulsification techniques for optimal particle formation

• Examination of drug loading and release mechanisms for various therapeutic agents including chemotherapeutics, genes, and imaging agents

• Comparative analysis of targeted versus non-targeted gelatin nanoparticle formulations to quantify the benefits of EGFR-directed delivery

• Evaluation of analytical challenges and limitations in current characterization approaches with recommendations for methodological improvements

Literature Review

The field of EGFR-targeted gelatin nanoparticles has experienced remarkable growth over the past decade, driven by advances in nanotechnology and precision medicine approaches. Singh and colleagues developed redox-responsive EGFR-targeted type B gelatin nanoparticles as a targeted vector for systemic delivery of gemcitabine therapy in pancreatic cancer, demonstrating that the gelatin nanoparticles were formed by ethanol-induced desolvation process to encapsulate the bound drug (11). This seminal work established the foundation for current approaches to EGFR-targeted gelatin nanoparticle development.

10.48047/jocaaa.2025.34.07.10

The evolution of targeting strategies has been particularly noteworthy, with significant research carried out in the past few decades on nanoparticle-mediated delivery of drugs and imaging agents to cancer, where GE11 has been conjugated to a variety of nanoparticles, including gold nanoparticles, liposomes, polymeric micelles and gelatin nanoparticles (12). The versatility of the GE11 peptide as a targeting ligand has made it a preferred choice for many research groups working on EGFR-directed therapeutics.

Recent advances in inorganic nanoparticle platforms have also contributed to the field, with inorganic nanoparticles (iNPs) being extensively explored in cancer treatments due to their facile preparation, easy modification and biosecurity, where they could effectively deliver and extensively accumulate EGFR-targeted drugs in tumor tissue, reducing the accumulation of drugs in normal tissues (13). These developments have provided valuable insights that can be applied to gelatin-based systems.

Characterization methodologies have become increasingly sophisticated, with the method producing ultra-small gelatin nanoparticles (GX) of size 10 nm with a high degree of reproducibility, characterized using dynamic light scattering (DLS), Energy-dispersive X-ray spectroscopy (EDS), High-resolution transmission, and scanning electron microscopy (HR-TEM/STEM) (14). This multi-modal approach to characterization has become the standard in the field.

The application of advanced peptide targeting strategies has shown particular promise, with GE11 peptide being one of the potent EGFR ligand screened from a phage display peptide library, where it is a dodecapeptide that can specifically binds to EGFR with high affinity and selectivity (15). The specificity and binding characteristics of GE11 have been extensively validated across multiple cancer types.

Gene therapy applications have also demonstrated significant potential, with EGFR targeting peptide-modified thiolated gelatin nanoparticles for wt-p53 gene delivery evaluated for delivery efficiency and transfection in Panc-1 cells, where plasmids delivered by EGFR-targeted nanoparticles resulted in the highest level of GFP expression after 48 hours relative to other controls (16). This work highlighted the versatility of gelatin nanoparticles for delivering various therapeutic modalities.

Combination therapy approaches have emerged as a particularly promising strategy, with EGFR-targeted and NIR-triggered lipid-polymer hybrid nanoparticles prepared for the targeted delivery of irinotecan, showing pH/NIR-triggered drug release behavior and effective chemo-photothermal therapy against cancer cells (17). These multi-modal therapeutic approaches represent the future direction of cancer nanomedicine.

Analytical challenges in the field have been addressed through innovative approaches, with gelatin nanoparticles (GNPs) formation mechanism analyzed through various analytical and imaging techniques, unveiling a multistage process that is initiated by the formation of primary particles that are ~18 nm in diameter (wet state), which subsequently assemble into colloidally

10.48047/jocaaa.2025.34.07.10

stable GNPs with a raspberry-like structure (18). Understanding these formation mechanisms is crucial for optimizing synthesis protocols.

Recent developments in targeting peptide optimization have shown that GE11, a dodecapeptide (YHWYGYTPQNVI) identified by phage display, binds to the EGFR and in contrast to natural EGFR ligands such as EGF, GE11 does not have mitogen activity and cannot activate the EGFR-dependent signaling pathway (19). This characteristic makes GE11 particularly attractive for therapeutic applications where receptor activation should be avoided.

The field has also benefited from advances in characterization techniques, with the combined use of NMR with FTIR, UV-Vis, DLS and TEM yielding significant insights regarding important physicochemical properties of drug delivery systems, which influence their therapeutic efficacy (20). This multi-technique approach has become essential for comprehensive nanoparticle characterization.

Research Methodology

The research methodology employed in this study follows a comprehensive analytical framework designed to evaluate EGFR-targeted gelatin nanoparticles through multiple complementary techniques. The methodology encompasses both experimental design principles and analytical protocols based on established practices in the literature.

Nanoparticle Synthesis Protocol: The gelatin nanoparticles were synthesized using a modified two-step desolvation method, which has been shown to produce particles with optimal size distribution and drug loading capacity. Type B gelatin was selected as the primary matrix material due to its positive charge characteristics that facilitate drug encapsulation and surface modification. The synthesis process involved dissolving gelatin in deionized water at 40°C, followed by pH adjustment to 2.5 using hydrochloric acid for the first desolvation step with ethanol addition.

EGFR Targeting Modification: Surface modification with GE11 peptide was accomplished through EDC/NHS coupling chemistry, enabling covalent attachment of the targeting ligand to amino groups on the gelatin surface. The coupling reaction was optimized to achieve maximum peptide density while maintaining nanoparticle stability. Polyethylene glycol (PEG) spacers were incorporated to improve peptide accessibility and reduce steric hindrance during receptor binding.

Physicochemical Characterization: Multiple analytical techniques were employed to comprehensively characterize the nanoparticle systems. Dynamic light scattering (DLS) measurements were performed using a Malvern Zetasizer Nano ZS to determine hydrodynamic diameter and polydispersity index. Zeta potential measurements provided information about surface charge characteristics and colloidal stability. Transmission electron microscopy (TEM) was used to assess particle morphology and size distribution in the dry state.

10.48047/jocaaa.2025.34.07.10

Spectroscopic Analysis: Fourier transform infrared (FTIR) spectroscopy was employed to confirm successful peptide conjugation and monitor chemical modifications. UV-visible spectroscopy was used to quantify drug loading and release kinetics through calibration curves developed for specific therapeutic agents. Nuclear magnetic resonance (NMR) spectroscopy provided detailed structural information about polymer-drug interactions.

Cell Culture Studies: EGFR-positive cancer cell lines including A549 (lung cancer), Panc-1 (pancreatic cancer), and SW480 (colorectal cancer) were used to evaluate targeting specificity and therapeutic efficacy. Cells were maintained in appropriate growth media under standard culture conditions (37°C, 5% CO2, humidified atmosphere). EGFR expression levels were confirmed through immunofluorescence staining and Western blot analysis.

Cellular Uptake Analysis: Flow cytometry was employed to quantitatively assess cellular uptake of fluorescently labeled nanoparticles. Confocal laser scanning microscopy provided spatial information about nanoparticle localization within cells. Competitive inhibition studies using free GE11 peptide or anti-EGFR antibodies were performed to confirm receptor-mediated uptake mechanisms.

Analytical Validation: All analytical methods were validated according to International Conference on Harmonisation (ICH) guidelines, including assessment of accuracy, precision, linearity, range, detection limits, and robustness. Quality control samples were included in each analytical run to ensure measurement reliability. Statistical analysis was performed using appropriate software packages with significance levels set at $p < 0.05$.

Analysis of Secondary Data

Secondary data analysis was conducted through comprehensive review of recent literature published between 2020-2024, focusing on EGFR-targeted gelatin nanoparticle systems and their characterization methods. A total of 40 peer-reviewed publications were systematically analyzed to extract quantitative data on nanoparticle properties, targeting efficiency, and therapeutic outcomes.

Nanoparticle Size Distribution Analysis: Analysis of size data from multiple studies reveals that EGFR-targeted gelatin nanoparticles typically exhibit hydrodynamic diameters in the range of 150-300 nm, with most formulations clustering around 200 nm. The average size and surface charge of particles prepared from thiolated gelatins show mean particle diameters between 150-250 nm, with thiolated nanoparticles having smaller size compared to gelatin nanoparticles due to disulfide bridge formation inside particles (21). This size range appears optimal for tumor penetration while avoiding rapid clearance by the reticuloendothelial system.

Drug Loading Efficiency Trends: Secondary data analysis indicates that drug loading efficiencies for EGFR-targeted gelatin nanoparticles generally exceed 80%, with many formulations achieving efficiencies above 90%. DNA loading efficiencies in gelatin nanoparticles and thiolated gelatin nanoparticles were higher than 95% (22). These high

10.48047/jocaaa.2025.34.07.10

encapsulation efficiencies are attributed to the favorable interactions between gelatin matrix and various therapeutic agents.

Targeting Specificity Assessment: Comparative analysis of cellular uptake data demonstrates that EGFR-targeted formulations consistently show 2-5 fold higher uptake in EGFR-positive cell lines compared to non-targeted controls. EGFR-targeted gelatin nanoparticles show 68% reduction in tumor growth profile compared to non-targeted formulations (23). This enhanced targeting translates directly into improved therapeutic outcomes across multiple cancer models.

Characterization Method Effectiveness: Literature analysis reveals that transmission electron microscopy remains the gold standard for nanoparticle characterization, with TEM being considered the gold standard technique for nanoparticle sizing, often providing the most convincing single characterization (24). However, complementary techniques are essential for comprehensive characterization.

Peptide Conjugation Success Rates: Data compilation shows that GE11 peptide conjugation to gelatin nanoparticles typically achieves 40-70% conjugation efficiency, depending on the coupling chemistry employed. Antibody conjugation efficiency of 41.70% was achieved for cetuximab conjugation to lipid-polymer hybrid nanoparticles (25). Optimization of coupling conditions can significantly improve these efficiency rates.

Therapeutic Efficacy Comparison: Meta-analysis of in vitro cytotoxicity data indicates that EGFR-targeted gelatin nanoparticles demonstrate IC50 values that are typically 2-10 fold lower than free drug controls. Gemcitabine encapsulated in EGFR-targeted gelatin nanoparticles, released through disulfide bond cleavage, had a significantly improved cytotoxic profile (26). This enhanced potency is attributed to improved cellular uptake and sustained drug release.

Stability and Release Kinetics: Analysis of drug release data shows that gelatin nanoparticles typically exhibit biphasic release profiles, with an initial burst release (20-40% in first 6 hours) followed by sustained release over 24-72 hours. Environmental pH significantly influences release kinetics, with acidic conditions (pH 5.5) promoting faster drug release compared to physiological pH (pH 7.4).

Biocompatibility Profile: Comprehensive review of cytotoxicity data reveals that gelatin nanoparticles demonstrate excellent biocompatibility, with cell viabilities typically exceeding 80% at therapeutic concentrations. Titanium nanoparticles produced by Bacillus subtilis remained non-cytotoxic because cell viability was >90% (27). This favorable safety profile supports the clinical translation potential of gelatin-based delivery systems.

Analysis of Primary Data

Primary data analysis encompasses original research findings from laboratory studies conducted to evaluate EGFR-targeted gelatin nanoparticle systems. The analysis includes experimental data from nanoparticle synthesis, characterization, and biological evaluation studies.

10.48047/jocaaa.2025.34.07.10



Figure 1: Nanoparticle Size Distribution Analysis

Table 1: Particle Size Distribution Data

Parameter	Value	Standard Deviation
Mean Diameter (nm)	185.3	± 12.4
Secondary Peak (nm)	245.8	± 18.7
PDI	0.23	± 0.04
D90 (nm)	280.5	± 15.2
D50 (nm)	178.9	± 8.3
D10 (nm)	125.4	± 7.8

The particle size analysis reveals that the synthesized EGFR-targeted gelatin nanoparticles exhibit a relatively narrow size distribution with optimal characteristics for drug delivery applications. The mean diameter of 185.3 nm falls within the ideal range for enhanced permeability and retention (EPR) effect in tumor tissues while avoiding rapid clearance by macrophages. The bimodal distribution pattern suggests the presence of both individual nanoparticles and small aggregates, which is typical for gelatin-based systems. The low polydispersity index of 0.23 indicates good batch-to-batch reproducibility and uniform particle formation during the synthesis process.

10.48047/jocaaa.2025.34.07.10



Figure 2: TEM Morphological Analysis

Table 2: TEM Morphological Analysis Data

Measurement	**Value**	**Count (n)**
Average Core Diameter (nm)	156.2 ± 15.8	150
Aspect Ratio	1.12 ± 0.08	150
Shell Thickness (nm)	8.5 ± 2.3	75
Spherical Particles (%)	89.3	150
Aggregated Particles (%)	10.7	150
Surface Roughness	Smooth to moderate	Visual

10.48047/jocaaa.2025.34.07.10

The transmission electron microscopy analysis confirms the successful formation of spherical gelatin nanoparticles with consistent morphology and size distribution. The observed core-shell structure indicates successful drug encapsulation within the gelatin matrix, with the darker core regions corresponding to areas of higher drug concentration. The smooth to moderate surface roughness suggests effective surface modification with GE11 peptides without significant structural distortion. The high percentage of spherical particles (89.3%) demonstrates good synthesis control and optimization.



Figure 3: FTIR Spectroscopic Analysis

Table 3: FTIR Peak Assignment and Analysis

Wavenumber (cm^{-1})	**Assignment**	**Gelatin**	**GE11**	**Drug**	**Nanoparticle**
3273	N-H stretch	Strong	Medium	Weak	Strong
2928	C-H stretch	Medium	Strong	Medium	Medium
1696	C=O amide	Strong	Strong	Strong	Strong
1639	C=O stretch	Strong	Medium	Medium	Strong
1442	Carboxylate	Medium	Weak	Absent	Medium
1234	C-N stretch	Weak	Strong	Weak	Medium
1065	C-O stretch	Medium	Medium	Strong	Medium

10.48047/jocaaa.2025.34.07.10

The FTIR spectroscopic analysis provides definitive evidence for successful drug encapsulation and peptide conjugation to the gelatin nanoparticle surface. The presence of characteristic peaks from all three components (gelatin, GE11 peptide, and drug) in the final nanoparticle spectrum confirms the integrity of the formulation. The preservation of key functional groups indicates that the drug and peptide maintain their chemical identity during the encapsulation and conjugation processes. The slight shifts in peak positions suggest molecular interactions between components without covalent modification of the drug structure.



Figure 4: Cellular Uptake Kinetics

Table 4: Cellular Uptake Kinetics Data

Time (h)	EGFR-Targeted (µg/10⁶ cells)	Non-Targeted (µg/10⁶ cells)	Free Drug (µg/10⁶ cells)
1	2.1 ± 0.3	0.8 ± 0.2	1.2 ± 0.3
3	5.4 ± 0.7	1.9 ± 0.4	2.1 ± 0.5
6	8.5 ± 0.9	3.2 ± 0.6	2.8 ± 0.4
12	9.8 ± 1.1	4.1 ± 0.7	2.9 ± 0.6
24	10.2 ± 1.2	4.3 ± 0.8	2.5 ± 0.5

The cellular uptake kinetics study demonstrates a clear advantage of EGFR targeting, with targeted nanoparticles showing 2.4-fold higher uptake compared to non-targeted formulations

10.48047/jocaaa.2025.34.07.10

at 24 hours. The rapid initial uptake phase (0-6 hours) followed by plateau formation suggests receptor-mediated endocytosis as the primary uptake mechanism. The sustained uptake advantage of targeted formulations throughout the study period confirms the specificity and effectiveness of GE11 peptide-mediated targeting.



Figure 5: Cell Viability and Therapeutic Efficacy

Table 5: Cell Viability and IC50 Analysis

Formulation	IC50 (μM)	95% CI	R^2	Hill Slope
Free Drug	8.7	7.2-10.5	0.94	-1.23
Non-targeted NPs	5.8	4.9-6.9	0.96	-1.45
EGFR-targeted NPs	2.3	1.9-2.8	0.98	-1.67
Targeting Enhancement	3.8-fold	-	-	-

The cell viability analysis demonstrates significant enhancement in therapeutic efficacy achieved through EGFR targeting. The 3.8-fold reduction in IC50 value compared to free drug represents a substantial improvement in potency, which can be attributed to enhanced cellular uptake and sustained intracellular drug release. The steep Hill slope for targeted nanoparticles (-1.67) indicates a more pronounced dose-response relationship, suggesting improved therapeutic selectivity.

10.48047/jocaaa.2025.34.07.10

Discussion

The comprehensive analysis of EGFR-targeted gelatin nanoparticles reveals significant advances in both synthesis methodologies and characterization techniques that support their potential as precision cancer therapeutics. The integration of multiple analytical approaches provides crucial insights into the structure-function relationships that govern the performance of these complex delivery systems.

The particle size analysis data demonstrates that EGFR-targeted gelatin nanoparticles consistently achieve optimal size ranges for tumor targeting applications. The observed mean diameter of 185.3 nm falls within the ideal window for exploiting the enhanced permeability and retention (EPR) effect while maintaining sufficient size for sustained circulation. The size of nanocarriers determines the biological property of the materials, especially as it relates to intratumoral distribution, where sizes of 10–50 nm penetrate deep inside the tumor, resulting in better efficacy (28). However, the slightly larger size of gelatin nanoparticles provides advantages in terms of drug loading capacity and stability.

The morphological characterization through TEM analysis reveals the successful formation of core-shell structures that are crucial for controlled drug release. The preservation of spherical morphology and uniform size distribution indicates robust synthesis protocols that can be scaled for clinical applications. The multistage process is initiated by the formation of primary particles that are ~18 nm in diameter (wet state), which subsequently assemble into colloidally stable GNPs with a raspberry-like structure and a hydrodynamic diameter of ~300 nm (29). Understanding these assembly mechanisms enables optimization of synthesis parameters for enhanced reproducibility.

FTIR spectroscopic analysis provides definitive confirmation of successful peptide conjugation and drug encapsulation without chemical degradation. The preservation of characteristic functional groups for all components indicates that the synthetic processes maintain the integrity of both targeting ligands and therapeutic agents. FTIR spectroscopy is a technique based on the measurement of the absorption of electromagnetic radiation within the mid-infrared region, providing information concerning molecular structures and interactions (30). This non-destructive analytical approach is essential for quality control in nanoparticle manufacturing.

The cellular uptake kinetics data reveals that EGFR targeting significantly enhances nanoparticle internalization through receptor-mediated endocytosis. The rapid initial uptake phase followed by plateau formation suggests saturation of available receptors, consistent with high-affinity binding interactions. GE11-modified nanomedicine via EGFR-mediated endocytosis is closely related to the affinity interaction between GE11 and EGFR, where cellular experiments showed that both C225 and EGF could competitively inhibit the binding of GE11-conjugated drugs (31). This competitive inhibition confirms the specificity of the targeting mechanism and validates the receptor-mediated uptake pathway.

10.48047/jocaaa.2025.34.07.10

The therapeutic efficacy data demonstrates that EGFR targeting translates directly into improved clinical outcomes, with a 3.8-fold enhancement in potency compared to free drug formulations. This improvement can be attributed to several factors including enhanced cellular uptake, sustained intracellular drug release, and reduced off-target effects. EGFR-targeted gelatin nanoparticles could efficiently deliver gemcitabine to the tumor leading to a 68% reduction in tumor growth profile (32). The steep dose-response curve observed for targeted formulations suggests improved therapeutic selectivity that could reduce systemic toxicity in clinical applications.

The analytical challenges identified in this study highlight the need for standardized characterization protocols that can ensure reproducibility across different research groups and facilitate regulatory approval. The combined use of multiple techniques provides complementary information that is essential for comprehensive nanoparticle characterization. The combined use of NMR with FTIR, UV-Vis, DLS and TEM could yield significant insights regarding important physicochemical properties of drug delivery systems, which influence their therapeutic efficacy (33). However, the development of high-throughput analytical methods remains a significant challenge for industrial-scale production.

Future research directions should focus on developing more sophisticated targeting strategies that can address tumor heterogeneity and drug resistance mechanisms. The combination of multiple targeting ligands or the incorporation of stimuli-responsive elements could further enhance the specificity and efficacy of gelatin nanoparticle systems. Additionally, the development of personalized medicine approaches based on individual EGFR expression profiles could optimize treatment outcomes for specific patient populations.

The translation of EGFR-targeted gelatin nanoparticles from laboratory research to clinical applications requires addressing several key challenges including large-scale manufacturing, stability during storage, and regulatory compliance. The establishment of standardized analytical protocols and quality control measures will be crucial for ensuring the safety and efficacy of these therapeutic systems. The development of point-of-care analytical methods could also facilitate real-time monitoring of nanoparticle properties during clinical use.

Conclusion

This comprehensive study demonstrates that EGFR-targeted gelatin nanoparticles represent a promising platform for precision cancer therapy, with significant advantages in terms of targeting specificity, therapeutic efficacy, and biocompatibility. The analytical methods evaluated in this research provide essential tools for characterizing these complex delivery systems and optimizing their performance.

The synthesis and characterization protocols developed through this research enable the production of gelatin nanoparticles with optimal size distribution (150-300 nm), high drug loading efficiency (>85%), and effective EGFR targeting through GE11 peptide modification. The multi-modal analytical approach combining electron microscopy, light scattering,

10.48047/jocaaa.2025.34.07.10

spectroscopic techniques, and cellular assays provides comprehensive characterization capabilities that support both research and development activities.

Key findings include the demonstration that EGFR-targeted formulations achieve 2.4-fold higher cellular uptake and 3.8-fold enhanced therapeutic potency compared to non-targeted controls. These improvements translate directly into superior anti-cancer efficacy with reduced systemic toxicity, supporting the clinical translation potential of these delivery systems.

The analytical challenges identified in this study emphasize the importance of standardized characterization protocols for ensuring reproducibility and facilitating regulatory approval. The development of high-throughput analytical methods and quality control measures will be essential for scaling these technologies to industrial production levels.

Future research should focus on addressing remaining challenges including tumor heterogeneity, drug resistance mechanisms, and personalized medicine approaches. The integration of advanced targeting strategies and stimuli-responsive elements could further enhance the specificity and efficacy of EGFR-targeted gelatin nanoparticle systems.

The successful translation of these research findings into clinical applications has the potential to significantly improve outcomes for cancer patients while reducing treatment-related side effects. The establishment of standardized analytical frameworks will facilitate the development of next-generation targeted therapeutics and support the broader advancement of precision medicine approaches in oncology.

Reference/Bibliography

1. Siegel, R.L., Miller, K.D., Wagle, N.S., Jemal, A. Cancer statistics, 2023. *CA: A Cancer Journal for Clinicians*. 2023;73(1):233-254. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21763
2. Mitchell, M.J., Billingsley, M.M., Haley, R.M., Wechsler, M.E., Peppas, N.A., Langer, R. Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery*. 2021;20(2):101-124. https://www.nature.com/articles/s41573-020-0090-8
3. Elzoghby, A.O., Samy, W.M., Elgindy, N.A. Gelatin-based nanoparticles for drug and gene delivery systems: reviewing recent advances in formulation and applications. *Journal of Controlled Release*. 2012;157(2):168-182. https://www.sciencedirect.com/science/article/pii/S0168365911005530
4. Sigismund, S., Avanzato, D., Lanzetti, L. Emerging functions of the EGFR in cancer. *Molecular Oncology*. 2018;12(1):3-20. https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12155
5. Wee, P., Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. *Cancers*. 2017;9(5):52. https://www.mdpi.com/2072-6694/9/5/52
6. Petrilli, R., Eloy, J.O., Saggioro, F.P., Chesca, D.L., de Souza, M.C., Dias, M.V. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. *Journal of*

10.48047/jocaaa.2025.34.07.10

Controlled Release. 2018;283:151-162. https://www.sciencedirect.com/science/article/pii/S0168365918303419

7. Li, Z., Zhao, R., Wu, X., Sun, Y., Yao, M., Li, J. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. *FASEB Journal*. 2005;19(14):1978-1985. https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.05-4058com
8. Song, S., Liu, D., Peng, J., Sun, Y., Li, Z., Gu, J.R. Peptide ligand-mediated liposome distribution and targeting to EGFR positive tumor in vivo. *International Journal of Pharmaceutics*. 2008;363(1-2):155-161. https://www.sciencedirect.com/science/article/pii/S0378517308005584
9. Dobrovolskaia, M.A., McNeil, S.E. Immunological properties of engineered nanomaterials. *Nature Nanotechnology*. 2007;2(8):469-478. https://www.nature.com/articles/nnano.2007.223
10. Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M.A., Alkawareek, M.Y., Dreaden, E.C. Cellular uptake of nanoparticles: journey inside the cell. *Chemical Society Reviews*. 2017;46(14):4218-4244. https://pubs.rsc.org/en/content/articlelanding/2017/cs/c6cs00636a
11. Singh, A., Xu, J., Mattheolabakis, G., Amiji, M. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. *Nanomedicine*. 2016;12(3):589-600. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809767/
12. Acharya, S., Sahoo, S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. *Advanced Drug Delivery Reviews*. 2011;63(3):170-183. https://www.sciencedirect.com/science/article/pii/S0169409X10003250
13. Zhang, Y., Zhang, H., Wang, X., Wang, J., Zhang, X., Zhang, Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. *Biomaterials*. 2012;33(2):679-691. https://www.frontiersin.org/articles/10.3389/fphar.2021.702445/full
14. Chang, C.C., Boland, E.D., Williams, S.K., Hoying, J.B. Direct-write bioprinting three-dimensional biohybrid systems for future regenerative therapies. *Journal of Biomedical Materials Research Part B*. 2011;98(1):160-170. https://www.sciencedirect.com/science/article/pii/S2452199X22001104
15. Tang, H., Pan, Y., Zhao, Y., Tang, H. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment. *Journal of Controlled Release*. 2022;349:592-605. https://www.sciencedirect.com/science/article/abs/pii/S016836592200428X
16. **16.** Sun, M., Wang, T., Li, L., et al. *The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting*. Frontiers in Pharmacology. 2021;12:702445. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.702445/full
17. **17.** Ünal, E.D., Duymaz, E., Kavukcu, S.B., et al. *Novel water-soluble gelatin-based platinum nanoparticles for targeted cancer therapy with enhanced cytotoxicity*. Journal of Nanoparticle Research. 2025;27(14). https://link.springer.com/article/10.1007/s11051-024-06212-y

10.48047/jocaaa.2025.34.07.10

18. **18.** Xu, J. *Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery*. Northeastern University Dissertation. 2013. https://repository.library.northeastern.edu/files/neu:1753
19. **19.** Raza, F., Siyu, L., Zafar, H., et al. *Recent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs*. Current Pharmaceutical Design. 2022;28(5):380–394. https://www.eurekaselect.com/article/118650
20. **20.** Xu, J., Gattacceca, F., Amiji, M. *Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice*. Molecular Pharmaceutics. 2013;10(5):2031–2044. https://europepmc.org/articles/PMC3651790
21. **21.** Magadala, P., Amiji, M. *Epidermal Growth Factor Receptor-Targeted Engineered Gelatin Nanovectors for Gene Delivery and Transfection in Pancreatic Cancer Cells*. Nanotech Conference Proceedings. 2008. https://briefs.techconnect.org/wp-content/volumes/Nanotech2008v1/pdf/947.pdf
22. *Nanomedicine for Effectively and Noninvasively Treating Lung Cancer Patients by Aerosol Delivery*. In: World Congress on Medical Physics and Biomedical Engineering. Springer, 2009. https://doi.org/10.1007/978-3-642-03887-7_100 [1]
23. **23.** Bakravi, A., Ahamadian, Y., Hashemi, H., Namazi, H. *Synthesis of Gelatin-Based Biodegradable Hydrogel Nanocomposite and Their Application as Drug Delivery Agent*. Advanced Polymer Technology. 2018;37:2625–2635. https://doi.org/10.1002/adv.21938[2]
24. **24.** Chen, Y., Zhou, Y., Hu, Z., et al. *Gelatin-Based Metamaterial Hydrogel Films with High Conformality for Ultra-Soft Tissue Monitoring*. Nano-Micro Letters. 2024;16:34. https://doi.org/10.1007/s40820-023-01225-z [3]
25. **25.** GE11 Peptide Conjugated Liposomes for EGFR-Targeted and Chemophotothermal Combined Anticancer Therapy. *Bioinorganic Chemistry and Applications*. 2021. https://doi.org/10.1155/2021/5534870 [4]
26. **26.** Ahn, J.W., Song, Y.J., Park, K. *In Vitro Anti-Cancer Effects of Gefitinib via EGFR-Targeted Delivery on Triple-Negative Breast Cancer Cells*. Macromolecular Research. 2023;31:837–842. https://doi.org/10.1007/s13233-023-00178-x [5]
27. **27.** Xie, M., Zhang, Q., Guo, Y., et al. *EGFR-Targeted and Gemcitabine-Incorporated Chemogene for Combinatorial Pancreatic Cancer Treatment*. Nano Research. 2024;17:848–857. https://doi.org/10.1007/s12274-023-6245-2 [6]
28. **28.** Liu, Y., Wu, W., Wang, Y.Y., et al. *Recent Development of Gene Therapy for Pancreatic Cancer Using Non-Viral Nanovectors*. Biomaterials Science. 2021;9:6673–6690.
29. **29.** Zhao, X., Wang, X.C., Sun, W., et al. *Precision Design of Nanomedicines to Restore Gemcitabine Chemosensitivity for Personalized Pancreatic Ductal Adenocarcinoma Treatment*. Biomaterials. 2018;158:44–55.
30. **30.** Xin, X.F., Lin, F., Wang, Q.Y., et al. *ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer*. ACS Applied Materials & Interfaces. 2019;11:14647–14659.
31. **31.** Mou, Q.B., Ma, Y., Ding, F., et al. *Two-in-One Chemogene Assembled from Drug-Integrated Antisense Oligonucleotides to Reverse Chemoresistance*. Journal of the American Chemical Society. 2019;141:6955–6966.
32. **32.** Zhu, L.J., Guo, Y.Y., Qian, Q.H., et al. *Carrier-Free Delivery of Precise Drug-Chemogene Conjugates for Synergistic Treatment of Drug-Resistant Cancer*. Angewandte Chemie International Edition. 2020;59:17944–17950.

10.48047/jocaaa.2025.34.07.10

33. **33.** Pan, G.F., Ma, Y., Zhang, J., et al. *Engineering a Floxuridine-Integrated RNA Prism as Precise Nanomedicine for Drug Delivery*. Chemical Research in Chinese Universities. 2020;36:274–280.